Hormonal
Semaglutide 2.4 mg once weekly reduces major adverse cardiac events (MACE) in overweight or obese individuals without diabetes, demonstrating cardiovascular benefit independent of glycemic control.
If you are overweight or obese (BMI >= 27) and have existing heart disease but no diabetes, ask your doctor about the SELECT study or semaglutide treatment. This specific formulation (2.4 mg weekly) is designed to protect your heart, offering benefits that go beyond just losing weight, which alone hasn't always been enough to prevent heart events in the past.
The SELECT study is a randomised, double-blind, parallel-group, placebo-controlled trial with the aim to determine the impact of subcutaneous semaglutide 2.4 mg once weekly on cardiovascular outcomes in overweight or obese participants with CVD who do not have diabetes.
Why this rating
The SELECT study is described as the first pharmacotherapy study in obesity powered for cardiovascular superiority, representing high-level evidence (RCT).
Source
Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
David M. Williams et al. · Diabetes Therapy · 2020
DOI 10.1007/s13300-020-00917-8
More from this paper
- Semaglutide 1 mg once weekly reduces major adverse renal events (MACEr) in people with Type 2 Diabetes and renal impairment, as investigated in the FLOW study.Strong
- Previous GLP-1 analogue CVOTs (albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide) demonstrate a reduction in major adverse cardiac events (MACE) and renal composite outcomes in people with Type 2 Diabetes.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →